Selective laser trabeculoplasty versus 0·5% timolol eye drops for the treatment of glaucoma in Tanzania: a randomised controlled trial

• Main Authors: Heiko Philippin, MD (Author), Einoti Matayan, MMed (Author), Karin M Knoll, MD (Author), Edith Macha, Pharm Tech (Author), Sia Mbishi, BSc (Author), Andrew Makupa, MMed (Author), Cristóvão Matsinhe, MMed (Author), Vasco da Gama, MMed (Author), Mario Monjane, MMed (Author), Awum Joyce Ncheda, MMed (Author), Francisco Alcides Mulobuana, MMed (Author), Elisante Muna, MMed (Author), Nelly Fopoussi, MMed (Author), Gus Gazzard, ProfFRCOphth (Author), Ana Patricia Marques, PhD (Author), Peter Shah, ProfFRCOphth (Author), David Macleod, PhD (Author), William U Makupa, MMed (Author), Matthew J Burton, ProfPhD (Author)
• Formato: Livro
• Publicado em: Elsevier, 2021-11-01T00:00:00Z.
• Assuntos: article
• Acesso em linha: Connect to this object online.

Summary: Background: Glaucoma is a major cause of sight loss worldwide, with the highest regional prevalence and incidence reported in Africa. The most common low-cost treatment used to control glaucoma is long-term timolol eye drops. However, low adherence is a major challenge. We aimed to investig...